Depemokimab
Brand names: Exdensur · Active ingredient: Depemokimab
In short: EXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. Limitations of Use EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus .
What is Depemokimab used for?
EXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.
Limitations of Use
EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus .
Depemokimab dosage
The recommended dosage is 100 mg once every 6 months administered by subcutaneous injection into the upper arm, thigh, or abdomen avoiding 2 inches (5 cm) around the navel .
Missed Dose(s)
If a dose is missed, administer the missed dose as soon as possible and resume the once every 6‑month injection schedule from the date of when the missed dose was given.
•EXDENSUR is for subcutaneous use only.
•EXDENSUR should be administered by a healthcare provider.
•
Do not use EXDENSUR prefilled syringe if the security seal on the carton has been broken or if it has been dropped or damaged.
Preparation Instructions
1.
Remove the prefilled syringe from the refrigerator. Holding the middle of the prefilled syringe, take it out from the tray and allow it to sit at room temperature for 30 minutes prior to injection. Do not warm EXDENSUR injection in any other way. Do not remove the needle cap until you are ready to inject. Do not use the syringe if it has been left out of the carton for more than 8 hours.
2.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. EXDENSUR should be colorless to yellow to brown, clear to opalescent in color. Do not use EXDENSUR if the product exhibits discoloration, cloudiness, or particulate matter. It is normal to see an air bubble. Do not expel the air bubble prior to administration. Do not shake the device.
3.Choose the injection site; administer EXDENSUR into upper arm, thigh, or abdomen, avoiding the 2 inches (5 cm) around the navel. Do not give injections into areas where the skin is tender, bruised, red, or hard.
Administration Instructions
Figure 1. EXDENSUR Prefilled Syringe Components
1.
Pull Off the Gray Needle Cap
Remove the gray needle cap from the syringe by pulling it straight off, away from the needle.
Do not handle the syringe by the white plunger while removing the gray needle cap.
Do not put the gray needle cap back onto the syringe.
Inject within 5 minutes after removing the gray needle cap.
2.
Position the Syringe at the Injection Site
Use your free hand to gently pinch the skin around the cleaned injection site.
Do not handle the syringe by the white plunger while inserting the needle into the pinched skin.
Hold the middle of the syringe and insert the entire needle into the pinched skin at a 45 degree angle, as shown.
3.
Start the Injection and Fully Press the White Plunger
Slowly push down on the white plunger with your thumb to inject the full dose.
Make sure the white plunger is pushed all the way down until the stopper reaches the bottom of the syringe and all of the medication is injected.
4.
Slowly Lift Thumb After Injection Completes
Slowly lift your thumb up. …
How to take Depemokimab — instructions & advice from the label
Advise the patient to read the FDA‑approved patient labeling (Patient Information).
Hypersensitivity Reactions
Inform patients of hypersensitivity reactions, including anaphylaxis, that can occur following administration of EXDENSUR. Instruct patients to contact their healthcare provider if they experience symptoms of a hypersensitivity reaction .
Acute Asthma Symptoms or Deteriorating Disease
Inform patients that EXDENSUR does not treat acute asthma symptoms or acute exacerbations. Advise patients to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with EXDENSUR .
Risk Associated With Abrupt Reduction of Corticosteroid Dosage
Advise patients to not abruptly discontinue systemic or inhaled corticosteroids after initiation of EXDENSUR therapy. Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. Inform patients that reductions in corticosteroid dose, if appropriate, should be gradual and performed under the supervision of a healthcare provider . …
Warnings & precautions
Do not take this medicine if: None.
Hypersensitivity reactions, including anaphylaxis, can occur following administration of EXDENSUR. If a hypersensitivity reaction occurs, discontinue EXDENSUR and initiate appropriate therapy.
EXDENSUR should not be used to treat acute asthma symptoms or acute exacerbations. Do not use EXDENSUR to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with EXDENSUR.
Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. Do not abruptly discontinue systemic or inhaled corticosteroids upon initiation of EXDENSUR therapy. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the supervision of a healthcare provider.
Eosinophils may be involved in the immunological response to some helminth infections. Patients with pre‑existing helminth infections were excluded from participation in the clinical trials. It is unknown if EXDENSUR will influence a patient’s response against parasitic infections. Patients with pre‑existing helminth infections should be treated for their infection prior to initiation of EXDENSUR therapy. If patients become infected while receiving treatment with EXDENSUR and do not respond to anti‑helminth treatment, discontinue treatment with EXDENSUR until the infection resolves.
Depemokimab side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling:
•Hypersensitivity Reactions .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of EXDENSUR was based on a pooled safety population from 2 replicate, randomized, double‑blind, parallel‑group, placebo‑controlled, multicenter clinical trials (SWIFT‑1 and SWIFT‑2) of 52 weeks duration. The 2 trials included 762 adult and pediatric patients 12 years of age and older with asthma, who received either EXDENSUR 100 mg or placebo administered subcutaneously once every 6 months in addition to their existing background medications for asthma . A total of 475 patients received 2 doses of EXDENSUR 100 mg in these trials.
Adverse reactions with EXDENSUR with incidence of ≥4% are shown in Table 1. …
About this medicine
Depemokimab‑ulaa is an interleukin‑5 (IL‑5) antagonist monoclonal antibody (humanized immunoglobulin G1 [IgG1] kappa). Depemokimab‑ulaa is produced by recombinant DNA technology in Chinese hamster ovary cells. The estimated molecular weight of depemokimab‑ulaa is 149 kDa.
EXDENSUR (depemokimab‑ulaa) injection is a sterile, preservative‑free, colorless, yellow to brown, clear to opalescent solution for subcutaneous use.
EXDENSUR injection is supplied in a single‑dose, 1‑mL, prefilled syringe with a fixed 29‑gauge, half‑inch needle with a needle guard. Each 1 mL delivers 100 mg depemokimab‑ulaa, (8.43 mg) arginine HCl, (0.017 mg) edetate disodium, (1.41 mg) histidine, (2.29 mg) L‑histidine HCl monohydrate, (0.20 mg) polysorbate 80, (61.6 mg) trehalose, and Water for Injection with a pH of 6.0. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 30332b20-2ac0-42ad-a775-d3ca7f5fe29f. Read the full official label on DailyMed.
Related medicines
Albuterol Montelukast Fluticasone Hydroxyzine Fluticasone and Salmeterol Budesonide and Formoterol Fluticasone and Umeclidinium and Vilanterol Azelastine